No record found
No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).
| Erum Shakir Rahim | CEO |
| Dmytro Oliinyk | Chairperson |
| Hina Mir | Company Secretary |
CDC Share Registrar Services Limited CDC House, 99 - B, Block - B S.M.C.H.S., Main Shahra-e-Faisal Karachi
Yousuf Adil, Chartered Accountants
December
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Apr 29, 2026 | Transmission of Quarterly Financial Statements for the Period ended March 31, 2026 | View PDF |
| Apr 27, 2026 | Financial Results for the Quarter Ended March 31, 2026 | View PDF |
| Apr 9, 2026 | Transmission of Annual Financial Statements for the year ended 31-12-2025 | View PDF |
| Mar 26, 2026 | Financial Results for the year Ended 2025-12-31 | View PDF |
| Oct 29, 2025 | Transmission of Quarterly Report for the period ended September 30, 2025 | View PDF |
| Date | Title | Document |
|---|---|---|
| Apr 30, 2026 | Certified True Copy of The Resolutions passed by the shareholders in the Annual General Meeting held on April 30, 2026 | View PDF |
| Apr 20, 2026 | Board Meeting Quarter 1- 2026 | View PDF |
| Apr 9, 2026 | Notice of the Annual General Meeting | View PDF |
| Apr 8, 2026 | Prior Publication of Annual General Meeting Notice | View PDF |
| Mar 18, 2026 | Board Meeting Quarter 4, 2025 | View PDF |
Financials
All numbers in thousands (000's) except EPS
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 65,900,901 | 61,187,501 | 49,661,277 | 41,841,585 |
| Profit after Taxation | 10,025,315 | 6,536,047 | 533,953 | 2,462,892 |
| EPS | 31.48 | 20.52 | 1.68 | 7.73 |
| Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|
| Sales | 17,028,325 | 14,188,008 | 14,720,667 | 15,580,140 |
| Profit after Taxation | 2,610,704 | 2,037,285 | 2,068,811 | 2,126,547 |
| EPS | 8.20 | 6.40 | 6.50 | 6.68 |

Ratios
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 37.00 | 25.15 | 7.05 | 17.40 |
| Net Profit Margin (%) | 15.21 | 10.68 | 1.08 | 5.89 |
| EPS Growth (%) | 53.41 | 1,121.43 | (78.27) | (54.02) |
| PEG | 0.23 | 0.02 | (0.63) | (0.21) |









Feedback
Terms of Use
https://www.psx.com.pk